5Q Spectra

5Q Spectra is a clinical liquid biopsy and molecular diagnostics company focused on early cancer detection. The company's flagship product, Prostate Dx™ (also known as the PSB or Prostate Specific Biomarker test), is a blood-based test designed to determine whether clinically significant prostate cancer is present following an elevated PSA test. The underlying technology utilizes focused ultrasound and microbubbles to isolate and release cancer-associated microRNA (miRNA) from live, viable circulating tumor cells in the blood. Backed by over 15 years of research and development and a $500 million senior institutional funding relationship, 5Q Spectra is also expanding its diagnostic platform to target early-stage bladder and breast cancers.